Serena Williams at the Prelude to the 2024 Paris Olympics (Aurore Marechal/Abaca/Sipa USA via AP Images)
September 11, 2024 02:54 PM EDTUpdated 03:13 PM
Pharma
FDA+
Marketing

FDA crit­i­cizes Ab­b­Vie's 'mis­lead­ing' ad with Ser­e­na Williams

Zachary Brennan

Senior Editor

The FDA’s Of­fice of Pre­scrip­tion Drug Pro­mo­tion sent a let­ter to Ab­b­Vie late last month, call­ing out the com­pa­ny for what it said was a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times